A carregar...

The promise of CAR T-cell therapy in aggressive B-cell lymphoma

Relapsed or refractory aggressive B-cell lymphoma has an extremely poor prognosis and efforts to develop novel therapies for these patients have failed for almost four decades until the advent of chimeric antigen receptor (CAR) T-cell therapy. Within the last one year, two anti-CD19 CAR T-cell thera...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Best Pract Res Clin Haematol
Main Authors: Nair, Ranjit, Neelapu, Sattva S.
Formato: Artigo
Idioma:Inglês
Publicado em: 2018
Assuntos:
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6594830/
https://ncbi.nlm.nih.gov/pubmed/30213399
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.beha.2018.07.011
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!